Raging against the Sun offer as Taro acquisition stays on the cards
This article was originally published in Scrip
Executive Summary
Sun Pharma's offer to purchase the remaining 34% not held by it in Israel's Taro Pharmaceutical Industries faces more opposition with Raging Capital Management claiming that Sun's current offer price "grossly" undervalues Taro.